HIPEC as Up-Front Treatment in Locally Advanced Ovarian Cancer

Abstract

This study evaluated the effect of hyperthermic intraperitoneal chemotherapy with complete or near-complete cytoreduction on naïve ovarian cancer women; 5- and 10-year overall survival, disease-specific survival, and disease-free survival rates were significantly higher in these patients. These patients were also 67% less likely to die from any cause, 75% less likely to die from cancer, and 46% less likely to develop recurrence compared to patients that were treated with cytoreductive surgery alone. These favorable results highlight the need for future randomized controlled trials in order to further determine the effect of hyperthermic intraperitoneal chemotherapy.